Autoimmune @entity19 perform poorly in two-way active avoidance tasks, and the extent of this performance deficit appears to be related to the extent of @entity792 following developmental manipulations. In the current study, the pituitary hormone prolactin, which has immune-enhancing effects, was used to manipulate this @entity146 in adulthood. Prolatinergic manipulation may be achieved by the use of dopaminergic drugs. In two experiments, autoimmune NZB X NZW F1 (BW) @entity19 received either @entity1766 (PIM; a D2 antagonist) or @entity2847 ( @entity2847 ; a @entity935 agonist) in their drinking water. Control subjects received plain water. Following treatment, subjects were tested in an activity monitor, and active avoidance learning. Circulating PRL levels, as measured by RIA, were significantly increased by PIM and significantly decreased by @entity2847 . Neither drug affected circulating levels of autoantibodies to DNA or @entity6894 , a phospholipid. In Experiment 1, in which @entity19 were tested at 12 weeks of age, after 6 weeks of drug treatment, PIM treated animals of both sexes showed significantly more failures to escape the shock in avoidance conditioning, while @entity2847 did not have significant effects. In Experiment 2, in which @entity19 were tested at 16 weeks of age, after 12 weeks of drug treatment, @entity2847 treated females (males were not tested) showed significantly fewer failures to escape, while PIM did not have significant effects. The effects of PRL on behavior, and its relation to immune system function, are discussed.

Manipulation of XXXX in autoimmune @entity19 via prolactin.

@entity1766 :: ('MESH:D010868', 'Chemical') :: ['pimozide'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine', 'CB154'] @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral disorder'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmunity'] @entity6894 :: ('MESH:D002308', 'Chemical') :: ['cardiolipin']
@entity146 :: (MESH:D001523,Disease) :: ['behavioral disorders']
